Liu Xu-Sheng, Xie Jin, Wu Rui-Min, Xiao Gao-Chun, Zhang Yu, Pei Zhi-Jun
Department of Nuclear Medicine, Hubei Provincial Clinical Research Center for Precision Diagnosis and Treatment of Liver Cancer, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Hubei Provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Eur J Med Res. 2025 Mar 3;30(1):149. doi: 10.1186/s40001-025-02407-8.
Lung adenocarcinoma (LUAD) is one of the most common and lethal tumors. The identification of diagnostic and prognostic biomarkers is essential to improve patient prognosis and treatment outcomes.
The expression of minichromosome maintenance complex component 8 (MCM8) in 33 cancer types was analyzed using the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression. Tumor and normal tissues in LUAD were compared using TCGA data and validated against four datasets from the Gene Expression Omnibus. MCM8 expression was assessed by immunohistochemistry (IHC) using tissue microarrays. The diagnostic value of MCM8 was assessed by Receiver Operating Characteristic curve analysis, and its prognostic significance was determined by Kaplan-Meier analysis. The CIBERSORT method was used to examine immune infiltration. The association between MCM8 expression and m6A RNA methylation, glycolysis, and ferroptosis was assessed using the GEPIA online tool.
MCM8 is markedly overexpressed in many tumors including LUAD. MCM8 showed high accuracy for the diagnosis of LUAD, with an area under the curve of 0.849 in TCGA dataset. MCM8 overexpression in tumor tissues in LUAD was confirmed by IHC and shown to be associated with decreased overall survival and disease-specific survival. Analysis of immune cell infiltration showed that immune cell populations differed between high and low MCM8 expression groups. MCM8 expression correlated with that of genes associated with m6A RNA methylation, glycolysis, and ferroptosis.
MCM8 was identified as a promising diagnostic and prognostic marker in LUAD. The mechanism underlying the effect of MCM8 on cancer development and the immune response remains to be elucidated.
肺腺癌（LUAD）是最常见且致命的肿瘤之一。鉴定诊断和预后生物标志物对于改善患者预后及治疗结果至关重要。
利用癌症基因组图谱（TCGA）和基因型-组织表达数据库分析微小染色体维持复合体组分8（MCM8）在33种癌症类型中的表达情况。使用TCGA数据比较LUAD中的肿瘤组织和正常组织，并在基因表达综合数据库的四个数据集中进行验证。采用组织芯片通过免疫组织化学（IHC）评估MCM8的表达。通过受试者工作特征曲线分析评估MCM8的诊断价值，并用Kaplan-Meier分析确定其预后意义。使用CIBERSORT方法检测免疫浸润情况。利用GEPIA在线工具评估MCM8表达与m6A RNA甲基化、糖酵解和铁死亡之间的关联。
MCM8在包括LUAD在内的多种肿瘤中显著过表达。MCM8对LUAD的诊断具有较高准确性，在TCGA数据集中曲线下面积为0.849。通过IHC证实LUAD肿瘤组织中MCM8过表达，且其与总生存期和疾病特异性生存期降低相关。免疫细胞浸润分析表明，MCM8高表达组和低表达组的免疫细胞群体存在差异。MCM8表达与m6A RNA甲基化、糖酵解和铁死亡相关基因的表达相关。
MCM8被确定为LUAD中有前景的诊断和预后标志物。MCM8对癌症发展和免疫反应影响的潜在机制仍有待阐明。
